Electrolyte and Acid-Base Disturbances Induced by Clacineurin Inhibitors.
- Author:
Chang Hwa LEE
1
;
Gheun Ho KIM
Author Information
- Publication Type:Review
- Keywords: Calcineurin inhibitors; Acidosis; Hyperkalemia; Hypophosphatemia; Hypomagnesemia; Hypercalciuria
- MeSH: Acidosis; Aldosterone; Ammonium Compounds; Azotemia; Calcineurin; Cyclosporine; Drug Interactions; Humans; Hypercalciuria; Hyperkalemia; Hypophosphatemia; Magnesium; Peptidyl-Dipeptidase A; Plasma; Potassium; Tacrolimus
- From:Electrolytes & Blood Pressure 2007;5(2):126-130
- CountryRepublic of Korea
- Language:English
- Abstract: Nephrotoxicity is the most common and clinically significant adverse effect of calcineurin inhibitors. Cyclosporine and tacrolimus nephrotoxicity is manifested by both acute azotemia and chronic progressive renal disease and tubular zdysfunction. An elevation in the plasma potassium concentration due to reduced efficiency of urinary potassium excretion is common in cyclosporine-treated patients; it may be severe and potentially life-threatening with concurrent administration of an angiotensin converting enzyme inhibitor, which diminishes aldosterone release. Tubular injury induced by cyclosporine can also impair acid excretion. This may be presented as a hyperchloremic metabolic acidosis associated with decreased aldosterone activity and suppression of ammonium excretion by hyperkalemia. Some patients treated with cyclosporine develop hypophosphatemia due to urinary phosphate wasting. Renal magnesium wasting is also common presumably due to drug effects on magnesium reabsorption. Hypomagnesemia has also been implicated as a contributor to the nephrotoxicity associated with cyclosporine. Both cyclosporine and tacrolimus are associated with hypercalciuria. Attention must be paid to drug dose, side effects, and drug interactions to minimize toxicity and maximize efficacy.
